MedTrace Logo

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

NCT05244837 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-02-17

No results posted yet for this study

Summary

To explore the related biomarkers for safety and efficacy of the combination of chemotherapy and tislelizumab in non-small cell lung cancer

Conditions

  • Tislelizumab
  • Safety
  • Biomarker
  • Chemotherapy

Interventions

DRUG

Tislelizumab 200 mg

Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)

DRUG

Carboplatin AUC 5

Carboplatin AUC 5 IV Q3W

DRUG

pemetrexed 500mg/m2

Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer

DRUG

Paclitaxel 175mg/m2

Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer

DRUG

Nab-paclitaxel 260 mg/m2

nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer

Sponsors & Collaborators

  • Hao Long

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2022-07-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05244837 on ClinicalTrials.gov